Should Sarepta’s patents be seized by the government? Patient advocates pitch controversial drug pricing proposal
Six advocacy groups are sending a big ask to the federal government to lower the price of one rather expensive drug for Duchenne muscular dystrophy …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
